Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776287 | 0.93 | ABL1 (0.38) | ABL1GSK3BDYRK1ACYP3A4CYP2D6 | |
| SCHEMBL16238766 | 0.90 | TRPV1 (0.40) | TRPV1CACNA1H | |
| SCHEMBL16776288 | 0.88 | CHRM4 (0.39) | ABL1GSK3BDYRK1ACYP3A4CYP2D6 | |
| SCHEMBL16776268 | 0.86 | PRMT5 (0.35) | ABL1GSK3BDYRK1A | |
| SCHEMBL16776276 | 0.86 | GSK3B (0.40) | ABL1GSK3BDYRK1ACYP3A4CYP2D6 | |
| SCHEMBL17618747 | 0.86 | ABL1 (0.36) | ABL1GSK3BDYRK1ACACNA1H | |
| SCHEMBL16776286 | 0.86 | GSK3B (0.39) | ABL1TRPV1GSK3BDYRK1ACYP3A4 | |
| SCHEMBL16238591 | 0.83 | CYP11B2 (0.40) | ABL1GSK3BDYRK1ACYP3A4CYP2D6 | |
| SCHEMBL16249978 | 0.83 | CREBBP (0.42) | GSK3BDYRK1A | |
| SCHEMBL16776290 | 0.83 | SLC27A1 (0.38) | ABL1GSK3BDYRK1ACYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ABL1 4089/4885TRPV1 3670/4885GSK3B 1728/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | ABL1 4089/4885TRPV1 3670/4885GSK3B 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.